Loading the records…
Loading the records…
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Ketchum John B, holds the title of Director at Tango Therapeutics, Inc..
On 2026-11-17, the insider transacted 3,333 shares.The shares were transacted at a weighted average price of $24.08 per share, resulting in a total market-relevant value of $80K.
Ketchum John B (Director) sold $80K of $TNGX
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.